These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6716398)

  • 21. Inhibition of erythrocyte sickling by thiol reagents.
    Garel MC; Domenget C; Galacteros F; Martin-Caburi J; Beuzard Y
    Mol Pharmacol; 1984 Nov; 26(3):559-65. PubMed ID: 6493211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
    Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK
    Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of methyl acetimidate as an extracorporeal antisickling agent.
    Chao TL; Berenfeld MR; Gabuzda TG
    Am J Pediatr Hematol Oncol; 1984; 6(1):55-8. PubMed ID: 6711765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ektacytometric measurement of sickle cell deformability as a continuous function of oxygen tension.
    Sorette MP; Lavenant MG; Clark MR
    Blood; 1987 Jan; 69(1):316-23. PubMed ID: 3790727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural features required for the reactivity and intracellular transport of bis(3,5-dibromosalicyl)fumarate and related anti-sickling compounds that modify hemoglobin S at the 2,3-diphosphoglycerate binding site.
    Chatterjee R; Iwai Y; Walder RY; Walder JA
    J Biol Chem; 1984 Dec; 259(23):14863-73. PubMed ID: 6501320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of 2-imidazolines as anti-sickling agents.
    Chang H; Ewert SM; Nagel RL
    Mol Pharmacol; 1983 May; 23(3):731-4. PubMed ID: 6865916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.
    Abraham DJ; Gazze DM; Kennedy PE; Mokotoff M
    J Med Chem; 1984 Dec; 27(12):1549-59. PubMed ID: 6094807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative structure-activity relationship of phenoxy and benzyloxy acid derivatives as antisickling agents.
    Mahran MA
    Boll Chim Farm; 2000; 139(2):73-80. PubMed ID: 10920532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisickling effects of membrane-interacting compounds.
    Ohnishi ST
    Blood Cells; 1982; 8(2):337-43. PubMed ID: 6130805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences.
    Fabry ME; Kaul DK; Raventos-Suarez C; Chang H; Nagel RL
    J Clin Invest; 1982 Dec; 70(6):1315-9. PubMed ID: 7174796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells.
    Stuart J; Stone PC; Bilto YY; Keidan AJ
    J Clin Pathol; 1987 Oct; 40(10):1182-6. PubMed ID: 3119675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals.
    Noguchi CT; Rodgers GP; Schechter AN
    Prog Clin Biol Res; 1987; 240():381-91. PubMed ID: 3615501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular basis of antisickling agents.
    Franklin IM; Huehns ER
    Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
    [No Abstract]   [Full Text] [Related]  

  • 37. Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acid.
    Walder JA; Zaugg RH; Iwaoka RS; Watkin WG; Klotz IM
    Proc Natl Acad Sci U S A; 1977 Dec; 74(12):5499-503. PubMed ID: 271972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurements of red cell deformability and hydration reflect HbF and HbA
    Parrow NL; Tu H; Nichols J; Violet PC; Pittman CA; Fitzhugh C; Fleming RE; Mohandas N; Tisdale JF; Levine M
    Blood Cells Mol Dis; 2017 Jun; 65():41-50. PubMed ID: 28472705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of methyl acetyl phosphate, a covalent antisickling agent, on the density profiles of sickle erythrocytes.
    Ueno H; Yatco E; Benjamin LJ; Manning JM
    J Lab Clin Med; 1992 Jul; 120(1):152-8. PubMed ID: 1613320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
    Kennedy PE; Williams FL; Abraham DJ
    J Med Chem; 1984 Feb; 27(2):103-5. PubMed ID: 6694161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.